Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant in HIV-Infected Subjects Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir
NCT02154360Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aprepitant in human immunodeficiency virus infection (HIV), sponsored by University of Pennsylvania. Primary endpoints: Inflammatory Effects at 14 days, Safety at 28 days and 4 more. Started May 2014; status: completed.
02
Drugs
aprepitant
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02154360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154360.